• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MKI-1，一种新型的MASTL小分子抑制剂，通过激活PP2A在乳腺癌中发挥抗肿瘤和放射增敏活性。

MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer.

作者信息

Kim Ah-Young, Yoon Yi Na, Leem Jiyeon, Lee Jee-Young, Jung Kwan-Young, Kang Minsung, Ahn Jiyeon, Hwang Sang-Gu, Oh Jeong Su, Kim Jae-Sung

机构信息

Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.

Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon, South Korea.

出版信息

Front Oncol. 2020 Sep 29;10:571601. doi: 10.3389/fonc.2020.571601. eCollection 2020.

DOI:10.3389/fonc.2020.571601
PMID:33117702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7550800/
Abstract

Although MASTL (microtubule-associated serine/threonine kinase-like) is an attractive target for anticancer treatment, MASTL inhibitors with antitumor activity have not yet been reported. In this study, we have presented a novel MASTL inhibitor, MKI-1, identified through screening and analysis. Our data revealed that MKI-1 exerted antitumor and radiosensitizer activities in and models of breast cancer. The mechanism of action of MKI-1 occurred through an increase in PP2A activity, which subsequently decreased the c-Myc protein content in breast cancer cells. Moreover, the activity of MKI-1 in the regulation of MASTL-PP2A was validated in a mouse oocyte model. Our results have demonstrated a new small-molecule inhibitor of MASTL, MKI-1, which exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer and

摘要

尽管微管相关丝氨酸/苏氨酸激酶样蛋白（MASTL）是抗癌治疗的一个有吸引力的靶点，但尚未有具有抗肿瘤活性的MASTL抑制剂的报道。在本研究中，我们展示了一种通过筛选和分析鉴定出的新型MASTL抑制剂MKI-1。我们的数据显示，MKI-1在乳腺癌的体内和体外模型中发挥抗肿瘤和放射增敏活性。MKI-1的作用机制是通过增加PP2A活性，进而降低乳腺癌细胞中的c-Myc蛋白含量。此外，在小鼠卵母细胞模型中验证了MKI-1在调节MASTL-PP2A方面的活性。我们的结果证明了一种新的MASTL小分子抑制剂MKI-1，它通过激活PP2A在乳腺癌体内和体外发挥抗肿瘤和放射增敏活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/ae86f8c124ef/fonc-10-571601-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/c53531e16ea8/fonc-10-571601-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/36fece050dfc/fonc-10-571601-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/712160463c19/fonc-10-571601-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/5ea57efbc111/fonc-10-571601-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/417d9eb6ad05/fonc-10-571601-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/b20dde299007/fonc-10-571601-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/ae86f8c124ef/fonc-10-571601-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/c53531e16ea8/fonc-10-571601-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/36fece050dfc/fonc-10-571601-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/712160463c19/fonc-10-571601-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/5ea57efbc111/fonc-10-571601-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/417d9eb6ad05/fonc-10-571601-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/b20dde299007/fonc-10-571601-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4a5/7550800/ae86f8c124ef/fonc-10-571601-g007.jpg

相似文献

1
MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer.MKI-1，一种新型的MASTL小分子抑制剂，通过激活PP2A在乳腺癌中发挥抗肿瘤和放射增敏活性。
Front Oncol. 2020 Sep 29;10:571601. doi: 10.3389/fonc.2020.571601. eCollection 2020.
2
Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes.一种靶向乳腺癌细胞和卵母细胞中MASTL-PP2A的新型MASTL抑制剂MKI-2的发现与特性研究
Pharmaceuticals (Basel). 2021 Jul 5;14(7):647. doi: 10.3390/ph14070647.
3
MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.MASTL 抑制通过激活 PP2A 促进有丝分裂灾难，从而抑制乳腺癌细胞的生长和放射抵抗性。
BMC Cancer. 2018 Jul 5;18(1):716. doi: 10.1186/s12885-018-4600-6.
4
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.PP2A-B55 抑制性激酶 MASTL/Greatwall 在乳腺癌中的治疗相关性。
Cell Death Differ. 2018 May;25(5):828-840. doi: 10.1038/s41418-017-0024-0. Epub 2017 Dec 11.
5
MASTL: A novel therapeutic target for Cancer Malignancy.MASTL：癌症恶性肿瘤的新型治疗靶标。
Cancer Med. 2020 Sep;9(17):6322-6329. doi: 10.1002/cam4.3141. Epub 2020 Jul 21.
6
MASTL overexpression promotes chromosome instability and metastasis in breast cancer.MASTL 过表达促进乳腺癌中的染色体不稳定性和转移。
Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.
7
AKT Regulates Mitotic Progression of Mammalian Cells by Phosphorylating MASTL, Leading to Protein Phosphatase 2A Inactivation.AKT 通过磷酸化 MASTL 调节哺乳动物细胞有丝分裂进程，导致蛋白磷酸酶 2A 失活。
Mol Cell Biol. 2020 Apr 28;40(10). doi: 10.1128/MCB.00366-18.
8
Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer.靶向抑制MASTL激酶活性可诱导乳腺癌细胞凋亡。
Life Sci. 2023 Dec 1;334:122250. doi: 10.1016/j.lfs.2023.122250. Epub 2023 Nov 4.
9
Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.治疗性天然化合物恩杂鲁胺和帕博西尼抑制 MASTL 激酶活性，防止乳腺癌细胞增殖。
Med Oncol. 2022 May 23;39(5):100. doi: 10.1007/s12032-022-01701-3.
10
Inflammatory cytokine-induced expression of MASTL is involved in hepatocarcinogenesis by regulating cell cycle progression.炎症细胞因子诱导的MASTL表达通过调节细胞周期进程参与肝癌发生。
Oncol Lett. 2019 Mar;17(3):3163-3172. doi: 10.3892/ol.2019.9983. Epub 2019 Jan 29.

引用本文的文献

1
The balance between B55α and Greatwall expression levels predicts sensitivity to Greatwall inhibition in cancer cells.B55α与Greatwall表达水平之间的平衡预示着癌细胞对Greatwall抑制的敏感性。
Nat Commun. 2025 Aug 27;16(1):8016. doi: 10.1038/s41467-025-62943-z.
2
Identification of druggable host dependency factors shared by multiple SARS-CoV-2 variants of concern.鉴定多个引起关注的 SARS-CoV-2 变异株共有的可用药宿主依赖性因子。
J Mol Cell Biol. 2024 Aug 26;16(3). doi: 10.1093/jmcb/mjae004.
3
Endosulfine alpha maintains spindle pole integrity by recruiting Aurora A during mitosis.

本文引用的文献

1
Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.MASTL 耗竭导致有丝分裂受到干扰，从而损害甲状腺肿瘤细胞的活力。
Cancer Lett. 2019 Feb 1;442:362-372. doi: 10.1016/j.canlet.2018.11.010. Epub 2018 Nov 14.
2
MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling.MASTL 通过促进 Wnt/β-catenin 信号通路诱导结肠癌进展和化疗耐药。
Mol Cancer. 2018 Aug 1;17(1):111. doi: 10.1186/s12943-018-0848-3.
3
MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
α-硫丹通过在有丝分裂过程中招募 Aurora A 来维持纺锤体极的完整性。
BMC Cancer. 2023 Dec 21;23(1):1263. doi: 10.1186/s12885-023-11742-0.
4
The MASTL-ENSA-PP2A/B55 axis modulates cisplatin resistance in oral squamous cell carcinoma.MASTL-ENSA-PP2A/B55轴调节口腔鳞状细胞癌中的顺铂耐药性。
Front Cell Dev Biol. 2022 Sep 28;10:904719. doi: 10.3389/fcell.2022.904719. eCollection 2022.
5
Scaffold-mediated switching of lymphoma metabolism in culture.支架介导的培养中淋巴瘤代谢转换
Cancer Metab. 2022 Oct 12;10(1):15. doi: 10.1186/s40170-022-00291-y.
6
SILAC kinase screen identifies potential MASTL substrates.SILAC 激酶筛选鉴定潜在的 MASTL 底物。
Sci Rep. 2022 Jun 22;12(1):10568. doi: 10.1038/s41598-022-14933-0.
7
MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels.MASTL在癌性和多能干细胞中富集，并影响OCT1/OCT4水平。
iScience. 2022 May 25;25(6):104459. doi: 10.1016/j.isci.2022.104459. eCollection 2022 Jun 17.
8
Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.治疗性天然化合物恩杂鲁胺和帕博西尼抑制 MASTL 激酶活性，防止乳腺癌细胞增殖。
Med Oncol. 2022 May 23;39(5):100. doi: 10.1007/s12032-022-01701-3.
9
Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes.一种靶向乳腺癌细胞和卵母细胞中MASTL-PP2A的新型MASTL抑制剂MKI-2的发现与特性研究
Pharmaceuticals (Basel). 2021 Jul 5;14(7):647. doi: 10.3390/ph14070647.
10
Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.磷酸化BRD4的表达与PP2A通路的激活状态显著相关，并在三阴性乳腺癌患者中显示出强大的预后价值。
Cancers (Basel). 2021 Mar 12;13(6):1246. doi: 10.3390/cancers13061246.
MASTL 抑制通过激活 PP2A 促进有丝分裂灾难，从而抑制乳腺癌细胞的生长和放射抵抗性。
BMC Cancer. 2018 Jul 5;18(1):716. doi: 10.1186/s12885-018-4600-6.
4
MASTL overexpression promotes chromosome instability and metastasis in breast cancer.MASTL 过表达促进乳腺癌中的染色体不稳定性和转移。
Oncogene. 2018 Aug;37(33):4518-4533. doi: 10.1038/s41388-018-0295-z. Epub 2018 May 10.
5
Identification of new inhibitors against human Great wall kinase using in silico approaches.利用计算机模拟方法鉴定新型人 Great wall 激酶抑制剂。
Sci Rep. 2018 Mar 20;8(1):4894. doi: 10.1038/s41598-018-23246-0.
6
Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression.Eya3与PP2A相互作用，诱导c-Myc稳定并促进肿瘤进展。
Nat Commun. 2018 Mar 13;9(1):1047. doi: 10.1038/s41467-018-03327-4.
7
Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer.人表皮生长因子受体2阴性乳腺癌细胞中的乳腺癌干细胞促成了人表皮生长因子受体2介导的放射抗性和分子亚型转化：复发性人表皮生长因子受体2阴性乳腺癌血清人表皮生长因子受体2的临床意义
Oncotarget. 2017 Dec 20;9(5):5811-5822. doi: 10.18632/oncotarget.23528. eCollection 2018 Jan 19.
8
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.PP2A-B55 抑制性激酶 MASTL/Greatwall 在乳腺癌中的治疗相关性。
Cell Death Differ. 2018 May;25(5):828-840. doi: 10.1038/s41418-017-0024-0. Epub 2017 Dec 11.
9
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.抗蠕虫药物氯硝柳胺抑制CIP2A并使非小细胞肺癌细胞中的肿瘤抑制蛋白磷酸酶2A重新激活。
Biochem Pharmacol. 2017 Nov 15;144:78-89. doi: 10.1016/j.bcp.2017.08.009. Epub 2017 Aug 13.
10
A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct.一种人类大墙激酶的第一代抑制剂，由最小激酶结构域构建体的结构和功能表征实现。
Oncotarget. 2016 Nov 1;7(44):71182-71197. doi: 10.18632/oncotarget.11511.